Literature DB >> 19571082

Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial.

Edgar Dawson1, Hyun W Bae, J Kenneth Burkus, Jeffery L Stambough, Steven D Glassman.   

Abstract

BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge has been shown to be a safe and effective replacement for iliac crest bone graft when used with a threaded fusion device in anterior lumbar interbody arthrodesis. Use of rhBMP-2 on an absorbable collagen sponge in posterolateral lumbar arthrodesis requires the addition of a bulking agent to provide resistance against compression and to serve as an osteoconductive scaffold for new bone formation.
METHODS: We performed a prospective, randomized, multicenter pilot study to investigate the use of rhBMP-2 on an absorbable collagen sponge combined with a ceramic-granule bulking agent as a replacement for autogenous iliac crest bone graft in single-level posterolateral lumbar arthrodesis with instrumentation. The investigational group (twenty-five patients) was treated with a 1.5 mg/mL solution of rhBMP-2 on two strips of absorbable collagen sponge (total dose of rhBMP-2, 12 mg) combined with 10 cm(3) of ceramic granules. The control group (twenty-one patients) received iliac crest bone graft. Clinical outcomes were assessed with use of well-established instruments. Radiographs were reviewed to assess consolidation of fusion.
RESULTS: Eighty-eight percent (twenty-two) of the twenty-five patients in the investigational group and 86% (eighteen) of the twenty-one patients in the control group were considered to have completed the twenty-four-month follow-up. At all follow-up intervals, there were significant improvements in the clinical outcome measures, including the Oswestry Disability Index (ODI) scores, Short Form-36 scores, and back and leg pain scores, in both groups. At twenty-four months, the improvement in the mean ODI score, as compared with the preoperative score, was 28.2 points in the investigational group and 23.0 points in the control group. By twenty-four months, 95% (eighteen) of nineteen patients in the investigational group compared with 70% (fourteen) of twenty in the control group had a radiographically documented fusion. The overall success rate was 81% (seventeen of twenty-one) in the investigational group and 55% (eleven of twenty) in the control group (p = 0.345).
CONCLUSIONS: Compared with an iliac crest bone graft, the combination of an absorbable collagen sponge soaked with rhBMP-2 and ceramic granules resulted in trends toward improvements in clinical outcomes and toward a higher rate of radiographic fusion. This combination of an osteoinductive agent with an osteoconductive matrix may be an effective replacement for autograft in single-level posterolateral lumbar arthrodeses with instrumentation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571082     DOI: 10.2106/JBJS.G.01157

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  37 in total

1.  Recombinant human BMP-2 increases the incidence and rate of healing in complex ankle arthrodesis.

Authors:  Mitchell S Fourman; Eugene W Borst; Eric Bogner; S Robert Rozbruch; Austin T Fragomen
Journal:  Clin Orthop Relat Res       Date:  2013-08-29       Impact factor: 4.176

2.  Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies.

Authors:  Abhijeet Kadam; Paul W Millhouse; Christopher K Kepler; Kris E Radcliff; Michael G Fehlings; Michael E Janssen; Rick C Sasso; James J Benedict; Alexander R Vaccaro
Journal:  Int J Spine Surg       Date:  2016-09-22

3.  Lessons from the infuse trials: do we need a classification of bias in scientific publications and editorials?

Authors:  Sohaib Hashmi; Mohamed Noureldin; Safdar N Khan
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

4.  A review of the current published spinal literature regarding bone morphogenetic protein-2: an insight into potential bias.

Authors:  Branko Skovrlj; Alejandro Marquez-Lara; Javier Z Guzman; Sheeraz A Qureshi
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

5.  A meta-analysis of bone morphogenetic protein-2 versus iliac crest bone graft for the posterolateral fusion of the lumbar spine.

Authors:  Gonzalo Mariscal; Jorge H Nuñez; Carlos Barrios; Pedro Domenech-Fernández
Journal:  J Bone Miner Metab       Date:  2019-07-10       Impact factor: 2.626

Review 6.  Clinical translation of controlled protein delivery systems for tissue engineering.

Authors:  Kara L Spiller; Gordana Vunjak-Novakovic
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

7.  Enhanced control of in vivo bone formation with surface functionalized alginate microbeads incorporating heparin and human bone morphogenetic protein-2.

Authors:  Sunny Akogwu Abbah; Jing Liu; James Cho Hong Goh; Hee-Kit Wong
Journal:  Tissue Eng Part A       Date:  2012-11-07       Impact factor: 3.845

8.  Bone graft materials for posterolateral fusion made simple: a systematic review.

Authors:  Matthew T Morris; Sandip P Tarpada; Woojin Cho
Journal:  Eur Spine J       Date:  2018-02-14       Impact factor: 3.134

Review 9.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

Review 10.  Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.

Authors:  Antonio Faundez; Clément Tournier; Matthieu Garcia; Stéphane Aunoble; Jean-Charles Le Huec
Journal:  Int Orthop       Date:  2016-03-10       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.